NCT00560638已完成2 期
A Double-Masked, Randomized, Placebo-Controlled Study of Loteprednol Etabonate Ophthalmic Suspension, 0.5% for the Treatment of Dry Eye Used Either TID or QID for a 2 Week Period
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 119
- 试验地点
- 1
- 主要终点
- Ocular discomfort during CAE exposure
研究概览
简要总结
This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •at least 18 years of age or older
- •able and willing to follow instructions, including participation in study assessments and able be present for the required study visits for the duration of the study
- •If female and of childbearing potential, were not pregnant, nursing, or planning a pregnancy. Women of childbearing potential were required to have a negative urine pregnancy test at the pre-screen visit and had to agree to use an acceptable method of mechanical or hormonal contraceptive for the duration of the study
- •a diagnosis of dry eye
- •a history of intermittent or regular artificial tear use within the past 3 months
- •best corrected visual acuity (BCVA) of +0.7 or better assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in one or both eyes
- •a fluorescein staining score of ≥ 1+ in at least one region in at least one eye at Visit 1 and before CAE exposure at Visits 2 and 3 OR a fluorescein staining score of ≥ 1+ in at least one region in at least one eye at Visit 1 and before CAE exposure at Visits 2 and 3 with a conjunctival redness score of ≥ 1.5+ at Visit 1 and before CAE exposure at Visits 2 and 3 in at least one eye
- •Demonstrated a response when exposed to the CAE at Visits 2 and 3
排除标准
- •clinically significant blepharitis or Meibomian Gland Dysfunction (MGD) or lid margin inflammation, particularly if systemic or topical medications were currently being used to treat any of these diagnoses
- •diagnosed with an on-going ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis), or preauricular lymphadenopathy, particularly if systemic or topical medications were currently being used to treat any of these diagnoses
- •Reported an ocular discomfort score of 4+ in both eyes at time 0 of CAE exposure at Visits 2 or 3
- •Wore contact lenses and refused to remove them for the duration of the study
- •previous laser in situ keratomileusis (LASIK) surgery
- •currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs and could not discontinue these medications for the duration of the study
- •presently taking any medication known to cause ocular drying that had not been a stable dose for at least 30 days
- •currently taking oral antihistamines that could not be discontinued during the study
- •a systemic disease, uncontrolled medical condition that in the opinion of the investigator could interfere with study measurements or subject compliance
- •received another experimental drug or device within 30 days prior to screening
研究组 & 干预措施
Loteprednol Etabonate TID
Experimental
loteprednol etabonate ophthalmic suspension, 0.5%, TID
干预措施: loteprednol etabonate ophthalmic suspension, 0.5% (Drug)
Loteprednol Etabonate QID
Experimental
loteprednol etabonate ophthalmic suspension, 0.5%, QID
干预措施: loteprednol etabonate ophthalmic suspension, 0.5% (Drug)
Vehicle
Placebo Comparator
vehicle of loteprednol etabonate
干预措施: vehicle of loteprednol etabonate (Drug)
结局指标
主要结局
Ocular discomfort during CAE exposure
时间窗: during CAE exposure
Corneal and conjunctival staining and conjunctival redness
时间窗: After CAE exposure
次要结局
- Blink rate, Tear film break-up time (TFBUT), and Ocular Protection Index (OPI)(before after CAE exposure)
- Ocular discomfort(collected in patient diaries)
- Corneal and conjunctival staining and conjunctival redness(before CAE exposure)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic RhinitisSeasonal Allergic RhinitisNCT023778953E Therapeutics Corporation73
已完成
1 期
A Multi-Center Study Subjects With Dry Eye SyndromeDry Eye SyndromeNCT01745887Eleven Biotherapeutics74
招募中
2 期
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)Atopic KeratoconjunctivitisNCT04296864Andover Eye Associates42
已完成
4 期
The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.Common ColdNCT02246166GlaxoSmithKline53
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058Cardiovascular Disease+Pulmonary DiseasePulmonary Arterial HypertensionNCT03708146Bial - Portela C S.A.157